Literature DB >> 16972176

LAT1 gene variants--potential factors influencing the clinical course of phenylketonuria.

Miroslaw Bik-Multanowski1, Jacek J Pietrzyk.   

Abstract

The LAT1 amino acid exchanger is responsible for phenylalanine transport across the blood-brain barrier. As phenylalanine excess in the brain leads to mental retardation in untreated patients with phenylketonuria, mutations of the LAT1 gene can be responsible for milder clinical manifestations (lower brain toxicity of hyperphenylalaninaemia) observed in some patients. The aim of this study was to screen for LAT1 gene mutations in phenylketonuric patients. Within the coding sequence of the gene, three polymorphism and one new mutation (G41D) were detected. The protein sequence change due to the mutation described could influence the clinical course of phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972176     DOI: 10.1007/s10545-006-0285-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  The fetal brain transcriptome and neonatal behavioral phenotype in the Ts1Cje mouse model of Down syndrome.

Authors:  Faycal Guedj; Jeroen L A Pennings; Millie A Ferres; Leah C Graham; Heather C Wick; Klaus A Miczek; Donna K Slonim; Diana W Bianchi
Journal:  Am J Med Genet A       Date:  2015-05-14       Impact factor: 2.802

2.  Carriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria.

Authors:  Miroslaw Bik-Multanowski; Anna Madetko-Talowska; Iwona Betka; Elzbieta Swieczka; Bozena Didycz; Karolina Orchel-Szastak; Kinga Bik-Multanowska; Ewa Starostecka; Joanna Jaglowska; Renata Mozrzymas; Joanna Zolkowska; Katarzyna Chyz; Dorota Korycinska-Chaaban
Journal:  Mol Genet Metab Rep       Date:  2020-08-21

3.  Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Keisuke Enomoto; Muneki Hotomi
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

4.  The rs113883650 variant of SLC7A5 (LAT1) gene may alter brain phenylalanine content in PKU.

Authors:  Miroslaw Bik-Multanowski; Kinga Bik-Multanowska; Iwona Betka; Anna Madetko-Talowska
Journal:  Mol Genet Metab Rep       Date:  2021-03-31

5.  Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier.

Authors:  K Klaassen; M Djordjevic; A Skakic; B Kecman; R Drmanac; S Pavlovic; M Stojiljkovic
Journal:  Mol Genet Metab Rep       Date:  2021-11-19

6.  Management precautions for risk of obesity are necessary among infants with PKU carrying the rs113883650 variant of the LAT1 gene: A cross-sectional study.

Authors:  Miroslaw Bik-Multanowski; Bozena Didycz; Kinga Bik-Multanowska
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

7.  Complex patterns of inheritance, including synergistic heterozygosity, in inborn errors of metabolism: Implications for precision medicine driven diagnosis and treatment.

Authors:  Jerry Vockley; Steven F Dobrowolski; Georgianne L Arnold; Ruben Bonilla Guerrero; Terry G J Derks; David A Weinstein
Journal:  Mol Genet Metab       Date:  2019-07-19       Impact factor: 4.797

8.  Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels.

Authors:  Kirsten K Ahring; Allan M Lund; Erik Jensen; Thomas G Jensen; Karen Brøndum-Nielsen; Michael Pedersen; Allan Bardow; Jens Juul Holst; Jens F Rehfeld; Lisbeth B Møller
Journal:  J Nutr Metab       Date:  2018-01-08

Review 9.  Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment.

Authors:  Jingshun Zhang; Ying Xu; Dandan Li; Lulu Fu; Xueying Zhang; Yigang Bao; Lianwen Zheng
Journal:  Front Chem       Date:  2020-10-20       Impact factor: 5.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.